Generic Name and Formulations:
Tesamorelin 2mg/vial; pwd for SC inj after reconstitution; preservative-free.
Indications for EGRIFTA:
For the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
Give by SC inj. Inject into abdomen, rotate inj sites. 2mg once daily.
Disruption of hypothalmic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumors/surgery, head irradiation, or head trauma. Active malignancy. Pregnancy (Cat.X).
Not for use in weight loss management. History of treated and stable malignancies. Discontinue in critically ill patients. Monitor IGF-1 levels closely; consider discontinuing if IGF-1 levels persistently elevated (eg, >3 SDS). Increased risk of impaired glucose tolerance or diabetes; monitor for changes in glucose metabolism. Monitor for worsening retinopathy in diabetic patients. Nursing mothers: not recommended.
Growth hormone releasing factor analogue.
Caution with concomitant drugs metabolized by CYP450 (eg, corticosteroids, sex steroids, anticonvulsants, cyclosporine). May inhibit 11β-hydroxysteroid dehydrogenase type 1; may need to increase maintenance and stress doses of glucocorticoid if needed for replacement in hypoadrenalism.
Arthralgia, inj site erythema/pruritus, pain in extremity, peripheral edema, myalgia, carpal tunnel syndrome, glucose intolerance, hypersensitivity reactions.
Single-use vial—30 (w. diluent)
Neurology Advisor Articles
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- Significant Variations in Epilepsy Surgical Strategy, Deficit Reporting Exist
- Smoking Promotes Disease Progression in Multiple Sclerosis
- Situation Framing, Language Can Influence Decision-Making
- Thrombolysis With Tenecteplase Is as Safe as Alteplase in Stroke Mimics
- FDA: Opioid Analgesic REMS Expanded to Include Immediate-Release Products